Keywords

Anemia, Interleukin-6 gene polymorphism, hepcidin HAMP gene polymorphism, Chronic kidney disease patients

References

[1]       Hentze, M. W., Muckenthaler, M. U. & Andrews, N. C. (2004). Balancing acts: molecular control of mammalian iron metabolism. Cell, 117, 285-297.

[2]       Liao, G., Xiang, J., Huang, X. & Yang, Y. (2012). A New “Mix-confined” Repeated Load Test for Evaluating Permanent Deformation of Asphalt Mixture. Journal of Testing and Evaluation, 40, 1177-1185.

[3]       Roy, A., Kucukural, A. & Zhang, Y. (2010). I-TASSER: a unified platform for automated protein structure and function prediction. Nature protocols, 5, 725.

[4]       Tim Goodnough L., Comin-Colet J., Leal-Noval S., et al. (2017). Management of anemia in patients with congestive heart  failure. Am J Hematol. 92(1): 88-93.

[5]       Muckenthaler M. U., Rivella S., Hentze M. W., Galy B. (2017). A red carpet for iron metabolism. Cell. 168(3): 344-361.

[6]       Canali S., Core A. B., Zumbrennen-Bullough K. B., et al. (2016). Activin B induces noncanonical SMAD1/5/8 signaling via BMP type i receptors in hepatocytes: evidence for a role in hepcidin induction by inflammation in male mice. Endocrinology. 157(3): 1146-1162.

[7]       Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T. & Kaplan, J. (2004). Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 306, 2090-2093.

[8]       Nemeth, E. & Ganz, T. (2009). The role of hepcidin in iron metabolism. Acta haematologica, 122, 78-86.

[9]       Aschemeyer S., Qiao B., Stefanova D., et al. (2018). Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin. Blood. 131(8): 899-910.

[10]    Hunter, H. N., Fulton, D. B., Ganz, T. & Vogel, H. J. (2002). The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. Journal of Biological Chemistry, 277, 37597-37603.

[11]    Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T. & Kishimoto, T. (1989). Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell, 58, 573-581.

[12]    Hirano, T., Akira, S., Taga, T. & Kishimoto, T. (1990). Biological and clinical aspects of interleukin 6. Immunology today, 11, 443-449.

[13]    Nishimoto, N. & Kishimoto, T. (2006). Interleukin 6: from bench to bedside. Nature Reviews Rheumatology, 2, 619.

[14]    Solak A. A., SöDERKVIST, B. K., MEDIN, C., HYLANDER, B. & HEIWE, S. (2012). Health-related quality of life in different stages of chronic kidney disease and at initiation of dialysis treatment. Health and quality of life outcomes, 10, 71.

[15]    Nairz M., Theurl I., Swirski F. K., Weiss G. (2017). “Pumping iron”-how macrophages handle iron at the systemic, microenvironmental, and cellular levels. Pflugers Arch., 469(3-4): 397-418.

[16]    Theurl I., Hilgendorf I., Nairz M., et al. (2016). On-demand erythrocyte disposal and iron recycling requires transient macrophages in the liver. Nat Med. 22(8): 945-951.

[17]    Khalil S., Delehanty L., Grado S, et al. (2018). Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. J Exp Med, 215(2): 661-679.

[18]    Zhang S., Macias-Garcia A., Velazquez J., Paltrinieri E., Kaufman R. J., Chen J. J. (2018). HRI coordinates translation by eIF2αP and mTORC1 to mitigate ineffective erythropoiesis in mice during iron deficiency. Blood. 131(4): 450-461.

[19]    Latour C, Wlodarczyk MF, Jung G, et al. (2017). Erythroferrone contributes to hepcidin repression in a mouse model of malarial anemia. Haematologica, 102(1): 60-68.

[20]    Docherty A. B., Turgeon A. F., Walsh T. S. (2018). Best practice in critical care: anaemia in acute and critical illness. Transfus Med. 28(2): 181-189.

[21]    Xu, J. Q., Mattock, M., Chusney, G. & Burt, D. (1997). NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia, 40, 1286.

[22]    Travis, S., González-Quintela, A., Campos, J., Quinteiro, C., Domínguez, F. & Loidi, L. (2010). Genetic study of the hepcidin gene (HAMP) promoter and functional analysis of the c.-582A> G variant. BMC genetics, 11, 110.